MT-2 and clavicle width claims: what the science actually says

What did @zygoless actually say?

The creator described melanotan II (MT-2) as triggering "melanogenesis" and claimed it makes you tan "at a rate of about 100x what you normally would." They also said it is "anti skin cancer, right? Because you're having less UV exposure." Finally, they noted it works by agonizing "melanocortin receptors" and "a couple others." That's a lot packed into a casual exchange, and not all of it holds up equally well.

To be fair, the conversation was informal and exploratory rather than a structured health claim. But 81,000 views means a lot of people are walking away with these impressions, so they deserve scrutiny.

Does the science back this up?

Partly. The melanocortin receptor mechanism is real and reasonably well described. The "100x" figure is invented, and the anti-skin cancer framing is far more complicated than presented.

MT-2 (melanotan II) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds primarily to MC1R and MC4R receptors. MC1R activation does stimulate melanin production, which is the biological basis for the tanning effect. That part the creator got right. Brennan et al. (2014, Pigment Cell and Melanoma Research) confirmed that MC1R agonism increases eumelanin synthesis in melanocytes, producing a tan without requiring UV radiation as the primary trigger.

The 100x claim, however, has no published basis. No peer-reviewed pharmacokinetic or clinical study has produced that number. It appears to be either street-level folklore or a wild extrapolation.

What did they get wrong (or right)?

The mechanism description is mostly right. The quantitative claim is wrong. The skin cancer framing is the most problematic part.

On mechanism: calling MT-2 a melanocortin receptor agonist is accurate. The "couple others" aside is vague but not wrong, since MT-2 also has affinity for MC3R and MC4R, the latter of which is responsible for well-documented side effects including spontaneous erections, nausea, and appetite suppression.

On the "100x" rate: there is no published figure supporting this. Clinical trials of afamelanotide, a closely related MC1R agonist that is actually FDA-approved in Europe and studied in the U.S. (Minder et al., 2010, New England Journal of Medicine), describe enhanced tanning but never quantify it this way. The 100x figure should be treated as unsupported.

On the skin cancer claim: this is where things get genuinely problematic. The logic, that less UV exposure means less skin cancer risk, is not wrong in isolation. But MT-2 itself has been associated with melanocytic nevi changes and possible melanoma activation in case reports. Langan et al. (2006, British Journal of Dermatology) documented lesion changes in MT-2 users. Calling it "anti skin cancer" without that context is misleading at best.

What should you actually know?

MT-2 is not approved by the FDA. It is sold as a research chemical and its safety profile in humans is poorly characterized outside small trials and case reports. The tanning effect is real but the risk picture is incomplete.

The reduced UV exposure logic has theoretical merit, but it assumes users actually avoid sun exposure, which behavioral data suggest many do not. Some users combine MT-2 with UV exposure to accelerate tanning further, which partially negates the claimed benefit.

There is also the MC4R side effect profile to consider. Nausea, facial flushing, and involuntary erections are commonly reported. These are not minor inconveniences. The compound is also unregulated, meaning purity and dosing in gray-market products are not guaranteed.

If you are considering any peptide therapy, this is not a decision to make based on a TikTok exchange. A supervised clinical context with bloodwork and monitoring is the only responsible framework.